Organization
VU University Medical Center, Amsterdam, Netherlands
7 abstracts
Abstract
14-3-3 ETA SERO-POSITIVITY MARKS MORE SEVERE DISEASE AND TITRES INFORM RESPONSE TO THERAPY, ALSO IN PATIENTS WITH LOWER CRP Org: Hospital for Special Surgery, New York, United States, VU University Medical Center, Amsterdam, Netherlands, Academic Medical Center, Amsterdam, AMC/ University of Amsterdam, Amsterdam, Netherlands, Rheumatology Patient Foundation, Cocoa, United States,
Abstract
“BACK TO BEING NORMAL”: THE PATIENT PERSPECTIVE ON REMISSION IN RHEUMATOID ARTHRITIS Org: VU University Medical Center, Amsterdam, Netherlands, University of the West of England, Bristol, United Kingdom, Rheumatology, Medical University of Vienna, Vienna, Austria, Bristol Royal Infirmary, Bristol, United Kingdom, Medical University of Vienna, Vienna, Austria,
Abstract
ANTI-INFLIXIMAB ANTIBODIES IN PATIENTS WITH AN INFUSION-RELATED ALLERGIC RESPONSE TO INFLIXIMABOrg: Ipsen, Sanquin Research, Immunoglobulin Research, Amsterdam, Netherlands, Rheumatology, Society of Patients with Rheumatism, Cracow, Poland, Slotervaart Ziekenhuis, Jan van Breemen Instituut,
Abstract
A partnership in implementation: adapting an osteoarthritis guidebook across european cultures – with patients, for patientsOrg: Research Institute for Primary Care and Health Sciences, Keele University, Keele, UK, VU University Medical Center, Amsterdam, Netherlands, Centre for Biomedical Research, University of Algarve, Algarve, Portugal, University of Southern Denmark, Odense, Denmark, University of Algarve, Algarve, Portugal,
Abstract
ANTI-CARBAMYLATED PROTEIN ANTIBODIES (ANTI-CARP) PRECEDE THE ONSET OF RHEUMATOID ARTHRITIS Org: Rheumatology, LUMC, Leiden, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, Division Diagnostic Services, Sanquin Blood Supply, Amsterdam, Netherlands, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, Division Diagnostic Services, 4Sanquin Blood Supply,
Abstract
BASELINE DEMOGRAPHIC AND DISEASE-STATE VARIABLES THAT MAY PREDICT A BETTER RESPONSE TO ETANERCEPT IN SUBJECTS WITH ANKYLOSING SPONDYLITIS: ASCEND Org: VU University Medical Center, Amsterdam, Netherlands, Rheumazentrum Ruhrgebiet, Herne, Germany, Pfizer Inc, Collegeville, PA, United States of America,
Abstract
A MIF PROMOTER POLYMORPHISM IS ASSOCIATED WITH THE SUSCEPTIBILITY TO PULMONARY ARTERIAL HYPERTENSION IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS PATIENTS Org: Biología Celular e Inmunología, Instituto de Parasitología y Biomedicina Lόpez Neyra (CSIC)., Armilla (Granada), Department of Internal Medicine, Hospital Valle de Hebrόn, Barcelona, Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Unidad de Enfermedades Sistémicas Autoinmunes, Department of Internal Medicine, Hospital Clínico Universitario San Cecilio, Granada, Department of Rheumatology, Hospital de la Santa CreuiSant Pau, Barcelona,